Paper16366606
New potential anticancer agents based on the anthranilic acid scaffold: synthesis and evaluation of biological activity.
Congiu C and 3 others. J Med Chem, 2005. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. New potential anticancer agents based on the anthranilic acid scaffold: synthesis and evaluation of biological activity. Papers, record 16366606. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16366606
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- New potential anticancer agents based on the anthranilic acid scaffold: synthesis and evaluation of biological activity.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| ortho-Aminobenzoates | Major topic |
| Animals | |
| Cell Line, Tumor | |
| Drug Evaluation, Preclinical | |
| Humans | |
| Mice | |
| Xenograft Model Antitumor Assays |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36551195 | Anticancer, Antimicrobial, and Antioxidant Activities of Organodiselenide-Tethered Methyl Anthranilates. | Biomolecules | 2022 | https://conductscience.org/library/papers/36551195 | PubMed |
| 35049922 | Secondary Metabolites from Marine-Derived Fungi and Actinobacteria as Potential Sources of Novel Colorectal Cancer Drugs. | Mar Drugs | 2022 | https://conductscience.org/library/papers/35049922 | PubMed |
| 34833915 | Mild Copper-Catalyzed, l-Proline-Promoted Cross-Coupling of Methyl 3-Amino-1-benzothiophene-2-carboxylate. | Molecules | 2021 | https://conductscience.org/library/papers/34833915 | PubMed |
| 29891789 | Design, Synthesis, Cytotoxic Evaluation and Molecular Docking of New Fluoroquinazolinones as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/29891789 | PubMed |
| 29385728 | The Design and Development of Potent Small Molecules as Anticancer Agents Targeting EGFR TK and Tubulin Polymerization. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/29385728 | PubMed |
| 23476416 | Anilinium-3-carboxyl-ate 3-carb-oxy-anilinium nitrate. | Acta Crystallogr Sect E Struct Rep Online | 2013 | https://conductscience.org/library/papers/23476416 | PubMed |
| 23209543 | The multicomponent approach to N-methyl peptides: total synthesis of antibacterial (-)-viridic acid and analogues. | Beilstein J Org Chem | 2012 | https://conductscience.org/library/papers/23209543 | PubMed |
| 21582409 | Hydrogen bonding in 2-carboxy-anilinium dihydrogen phosphite at 100 K. | Acta Crystallogr Sect E Struct Rep Online | 2009 | https://conductscience.org/library/papers/21582409 | PubMed |
| 21201160 | 2-Carboxy-anilinium chloride monohydrate. | Acta Crystallogr Sect E Struct Rep Online | 2008 | https://conductscience.org/library/papers/21201160 | PubMed |
| 19161316 | Use of the in vivo hollow fiber assay in natural products anticancer drug discovery. | J Nat Prod | 2009 | https://conductscience.org/library/papers/19161316 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16366606
GET https://conductscience.org/api/papers/v1/16366606/authors